Inclusion completed

Cancer type Title Country
Breast cancer A phase Ib/II, multicenter, open-label study to evaluate the efficacy of AUY922 in combination with trastuzumab in patients with locally advanced or metasatatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-con SE
Breast cancer A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to An-astrozole alone, in Post menopausal Women With Hormone Receptor positive, Endocrine T FI
Breast cancer A prospective phase II study to evaluate alternations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression efter initial exposure to trastuzumab-taxane based treatment SE
Breast cancer First in human study in HER2 positive primary breast cancer patient who are eligible for neoadjuvant chemotherapy DK
Breast cancer Randomized phase II study of afatinib alone or in combination with vinorelbine versus investigator’s choice of treatment in patients with HER2-positive breast cancer with pro-gressive brain metastases after trastuzumab or lapatinib based therapy FI
Cholangiocarcinoma A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma DK
Colorectal cancer Assessmant of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer SE
Colorectal cancer Randomized Double blind Placebo Controlled Gross-over Phase II study on the effects of Lactobacillus Rhamnosus GC supplementation in patients on 1st Line Chemotherapy treatment for Metastatic Coloretctal Cancer- the "lactAXE"- trial FI
Esophageal cancer Follow up of Phase I study of radiotherapy and platinum-Fluouracil based chemotherapy with cetuximab in locally advanced esopgael cancer DK
Gastric cancer Phase I-II study of traztuzumab combined with docetaxel, oxaliplatin and capecitabine in advanced or metastatic gastic or cardia cancer DK
Glioblastoma BIBF1120 in patient with glioblastoma and progression after standard therapy /temozolomide and radiotherapy (group 1) or after bevacizumab based secondline therapy (group 2) DK
Glioblastoma DC-CAST-GBM NO
Glioblastoma Phase I dose escalation of anti-PlGF combined with bevacizumab 10 mg/kg every 2 weeks in recurrent GBM DK
Head and Neck cancer An open-label, non-randomised, multicentre phase 1/2 trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment. SE
Head and Neck cancer Boron neutron capture therapy (BNCT) for the treatment of inoperable head and neck cancer FI
Leukemia A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q NO
Leukemia A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia NO
Leukemia A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia NO
Lung cancer A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment NO
Lung cancer A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment NO
Lung cancer A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer NO
Lung cancer CAUY922A2206 NSCLC NO
Lung cancer IDO Peptide Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients DK
Lung cancer Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma NO
Lymphoma A Two Stage Phase Ib Study to Investigate the Pharmocokinetics and Tolerability of Rituximab Subcutaneous Formulation in Pats With Follicular Lymphoma as Part of Maintenance Treatement FI
Lymphoma Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine,vindesine, temozolomi-de and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomi FI
Melanoma A randomised Phase II study of MK-3475 versus Chemotherapy in Pateients with Advanced Melanoma NO
Melanoma CA184025 Malign melanoma (inop. III and IV) NO
Melanoma CLGX818X2101 Locally advanced or mestastatic BRAF mutant melanoma NO
Melanoma DC-004 Unresectable metastases (Stage III or IV M1a-c-Malign melanoma) NO
Multiple diagnosis C08-315-01 Transdermally accessible tumour NO
Multiple diagnosis MOC31-PE Advanced mamma, lung, colorectal or prostate carcinoma NO
Multiple diagnosis Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK)in Patients with Advanced Cancer NO
Myeloma A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma DK
Myeloma Daratumumab (anti-CD38) in refractory multiple myeloma, first in humans DK
Ovarian cancer DC-006 Recurrent ovarian epithelial cancer NO
Pancreatic cancer Bay86-9766 And Gemcitabine in PAncreatic Cancer (BAGPAC) NO
Pancreatic cancer Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer SE
Pancreatic cancer Safety, pharmacokinetics and efficacy of AXP107-11 in patients with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the pancreas, stage III-IV. SE
Prostate cancer A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer FI
Prostate cancer A phase I/IIa study of UV1 vaccination in patients with hormone-sensitive metastatic prostate cancer NO
Prostate cancer Open, single-arm, multicenter, phase II trial investigating the safety of biweekly cabazi-taxel in metastatic castration resistant prostate cancer patients previously treated with docetaxel-containing regimen FI
Prostate cancer Safety and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer: open, non-randomised, uncontrolled, multicentre, multiple dose escalation study with randomised phase II expansion component FI
Sarcoma Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group NO
Skin cancer Combined treatment with Autologous Dendritic cells and T cells in patients with advanced Melanoma SE
Solide tumores A phase 1, open label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function SE
Solide tumores A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced or Metastatic Solid Tumor Malignancies DK
Solide tumores CMEK162X2102 All solid tumors with BRAF or RAF mutation NO
Solide tumores First study of intravenous catumaxumab (Removab) in patients with EpCam expressing epithelial solid tumors DK
Solide tumores Second generation Braf inhibitor (after lead compound vemurafenib) in Braf mutated solid tumors, and extension phase in melanomas and colorectal cancer DK
Solide tumores TWEAK-antibody in patients with Fn14 expressing solid tumors, first in humans study DK